Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

76.45 +1.94 (+2.60%)
Streaming Delayed Price Updated: 12:13 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,252,442
Open 75.03
Bid (Size) 76.36 (100)
Ask (Size) 76.55 (300)
Prev. Close 74.52
Today's Range 74.49 - 76.61
52wk Range 41.80 - 84.94
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool

Performance

YTD
-2.3%
-2.3%
1 Month
+17.0%
+17.0%
3 Month
+2.7%
+2.7%
6 Month
-0.0%
-0.0%
1 Year
+78.7%
+78.7%

More News

Read More
News headline image
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗
Via Chartmill
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗
Via MarketBeat
News headline image
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Participate in May and June Investor Conferences
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
Via MarketMinute
Topics Economy
News headline image
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
Via Chartmill
News headline image
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 76.45
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 07/02/26 12:13 PM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.27B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.